Tags

Type your tag names separated by a space and hit enter

Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects.
Eur Respir J. 1995 Jun; 8(6):905-12.ER

Abstract

When administered by inhalation, adenosine 5'-monophosphate (AMP) provokes dose-related bronchoconstriction in asthmatic subjects by a mechanism believed to involve mast cell mediator release. However, little is known of the change in airway responsiveness to AMP after cyclo-oxygenase blockade. The aim of this study was to investigate the effect of the potent cyclo-oxygenase inhibitor, lysine acetylsalicylate (L-ASA) administered by inhalation, on AMP-induced bronchoconstriction in a group of nine asthmatic subjects. The subjects studied attended the laboratory on six separate occasions to receive nebulized L-ASA (solution of 90 mg.ml-1) or matched placebo (glycine solution, 30 mg.ml-1) 15 min prior to bronchoprovocation tests with AMP, histamine and methacholine in a randomized, double-blind order. Changes in airway calibre were followed as forced expiratory volume in one second (FEV1) and agonist responsiveness was expressed as the provocative concentration causing a 20% fall in FEV1 from baseline (PC20). Administration of both L-ASA and glycine solution caused a small but significant acute fall in FEV1 from baseline, which returned to normal within 15 min. When compared to placebo, inhaled L-ASA reduced the airway responsiveness to AMP in all the subjects studied, the geometric mean (range) values for PC20 AMP increasing significantly from 36.3 (7.9-250.5) to 101.8 (27.2-1300) mg.ml-1 after placebo and L-ASA, respectively. Moreover, nebulized L-ASA induced a small but significant reduction in airway responsiveness to histamine, the geometric mean (range) PC20 values for histamine increasing from 2.77 (1.05-5.49) to 4.36 (1.69-11.24) mg.ml-1 after placebo and L-ASA, respectively.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Istituto Malattie Apparato Respiratorio, Università di Catania, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7589376

Citation

Crimi, N, et al. "Inhaled Lysine Acetylsalicylate (L-ASA) Attenuates the Bronchoconstrictor Response to Adenosine 5'-monophosphate (AMP) in Asthmatic Subjects." The European Respiratory Journal, vol. 8, no. 6, 1995, pp. 905-12.
Crimi N, Polosa R, Magrì S, et al. Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects. Eur Respir J. 1995;8(6):905-12.
Crimi, N., Polosa, R., Magrì, S., Prosperini, G., Milazzo, V. L., Santonocito, G., & Mistretta, A. (1995). Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects. The European Respiratory Journal, 8(6), 905-12.
Crimi N, et al. Inhaled Lysine Acetylsalicylate (L-ASA) Attenuates the Bronchoconstrictor Response to Adenosine 5'-monophosphate (AMP) in Asthmatic Subjects. Eur Respir J. 1995;8(6):905-12. PubMed PMID: 7589376.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects. AU - Crimi,N, AU - Polosa,R, AU - Magrì,S, AU - Prosperini,G, AU - Milazzo,V L, AU - Santonocito,G, AU - Mistretta,A, PY - 1995/6/1/pubmed PY - 1995/6/1/medline PY - 1995/6/1/entrez SP - 905 EP - 12 JF - The European respiratory journal JO - Eur. Respir. J. VL - 8 IS - 6 N2 - When administered by inhalation, adenosine 5'-monophosphate (AMP) provokes dose-related bronchoconstriction in asthmatic subjects by a mechanism believed to involve mast cell mediator release. However, little is known of the change in airway responsiveness to AMP after cyclo-oxygenase blockade. The aim of this study was to investigate the effect of the potent cyclo-oxygenase inhibitor, lysine acetylsalicylate (L-ASA) administered by inhalation, on AMP-induced bronchoconstriction in a group of nine asthmatic subjects. The subjects studied attended the laboratory on six separate occasions to receive nebulized L-ASA (solution of 90 mg.ml-1) or matched placebo (glycine solution, 30 mg.ml-1) 15 min prior to bronchoprovocation tests with AMP, histamine and methacholine in a randomized, double-blind order. Changes in airway calibre were followed as forced expiratory volume in one second (FEV1) and agonist responsiveness was expressed as the provocative concentration causing a 20% fall in FEV1 from baseline (PC20). Administration of both L-ASA and glycine solution caused a small but significant acute fall in FEV1 from baseline, which returned to normal within 15 min. When compared to placebo, inhaled L-ASA reduced the airway responsiveness to AMP in all the subjects studied, the geometric mean (range) values for PC20 AMP increasing significantly from 36.3 (7.9-250.5) to 101.8 (27.2-1300) mg.ml-1 after placebo and L-ASA, respectively. Moreover, nebulized L-ASA induced a small but significant reduction in airway responsiveness to histamine, the geometric mean (range) PC20 values for histamine increasing from 2.77 (1.05-5.49) to 4.36 (1.69-11.24) mg.ml-1 after placebo and L-ASA, respectively.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0903-1936 UR - https://www.unboundmedicine.com/medline/citation/7589376/Inhaled_lysine_acetylsalicylate__L_ASA__attenuates_the_bronchoconstrictor_response_to_adenosine_5'_monophosphate__AMP__in_asthmatic_subjects_ L2 - http://erj.ersjournals.com/cgi/pmidlookup?view=long&pmid=7589376 DB - PRIME DP - Unbound Medicine ER -